An unexpected finding that G2M checkpoint inhibitors may have a therapeutic effect on ATG5 high expression HNSCC and NPC, but more basic studies and clinical trials are still needed to validate the therapeutic effect. The gene discussed is ATG5; the disease is nasopharyngeal carcinoma.